MedTrace Logo

Post-marketing Surveillance Study on the Safety and Effectiveness of Abiraterone Acetate Among Adult Filipino Male Patients With Advanced Metastatic Castration Resistant Prostate Cancer

NCT01692483 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2015-12-02

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of abiraterone acetate in male Filipino patients with advanced metastatic castration resistant prostate cancer (CRPC) who have received prior chemotherapy containing a taxane.

Conditions

  • Prostate Neoplasms

Interventions

DRUG

Abiraterone acetate

Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily

DRUG

Prednisone

Prednisone or prednisolone 5 mg tablet taken orally twice daily

Sponsors & Collaborators

  • Janssen Pharmaceutica

    lead INDUSTRY

Principal Investigators

  • is Janssen Pharmaceutica, Philippines Clinical Trial · Janssen Pharmaceutica, Philippines

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2016-06-30
Completion
2016-06-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01692483 on ClinicalTrials.gov